Addison's Disease (Late-Onset)

Comprehensive Clinical Guide: Late-Onset Addison’s Disease (Primary Adrenal Insufficiency)

1. Introduction and Clinical Overview

Addison’s Disease, clinically defined as Primary Adrenal Insufficiency (PAI), is a chronic endocrine disorder characterized by the failure of the adrenal cortex to produce sufficient glucocorticoids (primarily cortisol) and mineralocorticoids (primarily aldosterone). While Addison’s disease is often diagnosed in early adulthood, "Late-Onset" refers to cases presenting in individuals aged 50 and older.

In the geriatric and late-adult population, the clinical presentation is notoriously insidious. Symptoms are frequently misattributed to age-related decline, depression, or comorbid chronic illnesses, leading to significant delays in diagnosis. Late-onset Addison’s requires a high index of clinical suspicion, as the progression to adrenal crisis can be rapid and fatal if precipitated by infection, surgery, or physical trauma.

2. Etiology and Pathophysiology

Etiological Factors

Unlike childhood-onset Addison’s, which is often tied to genetic syndromes (e.g., Autoimmune Polyglandular Syndrome Type 1), late-onset cases are predominantly acquired.

• Autoimmune Adrenalitis: The most common cause (approx. 70-80% in developed nations). It involves the destruction of the adrenal cortex via 21-hydroxylase autoantibodies.
• Infectious Processes: Tuberculosis remains a significant global cause, though systemic fungal infections (histoplasmosis, paracoccidioidomycosis) and opportunistic infections in immunocompromised patients are relevant in late-onset populations.
• Hemorrhagic Infarction: Bilateral adrenal hemorrhage, often associated with anticoagulant therapy or antiphospholipid syndrome.
• Metastatic Malignancy: Adrenal glands are common sites for metastasis (lung, breast, melanoma). Bilateral involvement can lead to acute or subacute primary insufficiency.
• Iatrogenic/Drug-Induced: Prolonged use of medications that inhibit steroidogenesis (e.g., ketoconazole, etomidate) or immune checkpoint inhibitors (e.g., ipilimumab, nivolumab) which are increasingly used in geriatric oncology.

Pathophysiological Mechanism

The hallmark of Addison’s is the loss of the adrenal cortex layers:
1. Zona Glomerulosa: Loss of aldosterone leads to salt wasting, hyperkalemia, and metabolic acidosis.
2. Zona Fasciculata: Loss of cortisol leads to hypoglycemia, inability to handle physiological stress, and increased ACTH production (due to loss of negative feedback).
3. Zona Reticularis: Loss of adrenal androgens, contributing to loss of libido and decreased axillary/pubic hair in women.

3. Clinical Staging and Presentation

Staging of Adrenal Insufficiency

Standard Clinical Presentation

In late-onset patients, the symptoms are often non-specific:
* Fatigue and Weakness: Often described as "debilitating" and worsening throughout the day.
* Gastrointestinal Distress: Anorexia, weight loss, nausea, vomiting, and abdominal pain.
* Hyperpigmentation: Specifically in skin creases, palmar creases, and buccal mucosa (due to elevated ACTH/MSH).
* Postural Hypotension: Dizziness or syncope upon standing due to volume depletion.
* Psychiatric Manifestations: Confusion, depression, or apathy.

4. Differential Diagnosis

Distinguishing Addison’s from other geriatric conditions is critical.

• Hypothyroidism: Shares symptoms of fatigue and weakness.
• Depression/Dementia: Shares symptoms of apathy, weight loss, and confusion.
• Chronic Kidney Disease (CKD): Shares hyperkalemia and hyponatremia.
• Gastrointestinal Malignancy: Shares weight loss and abdominal pain.
• Secondary Adrenal Insufficiency: Distinguished by the lack of hyperpigmentation and usually normal aldosterone/potassium levels (due to intact RAAS).

5. Diagnostic Testing Protocols

The diagnosis of Addison’s involves a two-step approach: confirming the insufficiency and determining the etiology.

Step 1: Biochemical Confirmation

• Morning Serum Cortisol (08:00): A level <3 µg/dL is highly suggestive; >18 µg/dL generally excludes it.
• ACTH Stimulation Test (Gold Standard): Administration of 250 µg of synthetic ACTH (Cosyntropin). Failure to increase cortisol to >18 µg/dL after 30-60 minutes confirms adrenal insufficiency.
• Plasma ACTH: Significantly elevated in primary disease (differentiates from secondary).

Step 2: Etiological Assessment

• 21-Hydroxylase Antibodies: To confirm autoimmune etiology.
• Imaging (CT Abdomen): To assess adrenal size. Small, atrophic glands suggest autoimmune; enlarged glands suggest infection, hemorrhage, or malignancy.
• Infectious Workup: TB-Gold test or fungal serology if travel/history suggests.

6. Treatment and Management

Hormone Replacement Therapy (HRT)

The goal is to replicate the physiological circadian rhythm of cortisol.

1. Glucocorticoid Replacement:
   • Hydrocortisone (15–25 mg/day) in divided doses (e.g., 10 mg AM, 5 mg noon, 5 mg afternoon).
   • Prednisolone (3–5 mg/day) as an alternative for better compliance.
2. Mineralocorticoid Replacement:
   • Fludrocortisone (0.05–0.2 mg/day). Dosage is titrated based on blood pressure, plasma renin activity, and serum potassium levels.
3. DHEA Replacement (Optional):
   • Considered for women with low libido or persistent fatigue despite adequate GC/MC replacement.

"Sick Day" Rules

Patients must be educated on increasing their glucocorticoid dose during illness:
* Minor Illness (Fever, mild infection): Double the daily dose.
* Severe Trauma/Surgery: Parenteral hydrocortisone (100 mg IV/IM) followed by continuous infusion or frequent dosing.

7. Risks, Contraindications, and Complications

• Adrenal Crisis: The most severe complication. Symptoms include profound hypotension, delirium, and shock. Requires immediate IV fluids and high-dose hydrocortisone.
• Overtreatment: Cushingoid features, weight gain, hypertension, and osteoporosis (a major risk in the elderly).
• Undertreatment: Persistent fatigue, electrolyte imbalance, and risk of crisis.
• Contraindications: Caution with drugs that induce hepatic enzymes (e.g., rifampin, phenytoin), which accelerate cortisol metabolism and may necessitate dosage increases.

8. Long-Term Prognosis

With strict adherence to medication and patient education, the prognosis for late-onset Addison’s is excellent. Life expectancy is generally normal. However, quality of life (QoL) studies indicate that patients frequently report lower QoL due to the constant vigilance required for "sick day" management and the psychological stress of potential adrenal crisis. Regular monitoring of bone mineral density is essential in the late-onset population to mitigate GC-induced osteoporosis.

9. Frequently Asked Questions (FAQ)

1. Is Late-Onset Addison’s the same as "Adrenal Fatigue"?
No. "Adrenal Fatigue" is a non-medical, pseudoscientific term. Addison’s is a clinically verified, life-threatening endocrine failure requiring hormone replacement.

2. Why is it harder to diagnose in older adults?
Symptoms like fatigue, weight loss, and dizziness are common in aging. Clinicians often attribute these to other comorbidities, delaying testing.

3. Does skin hyperpigmentation always occur?
It is a hallmark of primary disease, but it may be subtle or absent in some patients, especially if the disease onset is rapid.

4. Can I stop medication if I feel better?
Never. Addison’s is a permanent condition. Stopping medication will lead to a fatal adrenal crisis.

5. What should I do if I’m vomiting and cannot keep pills down?
This is an emergency. You require immediate medical attention for parenteral (IV/IM) hydrocortisone.

6. Do I need to wear a medical alert bracelet?
Absolutely. In the event of an accident or emergency where you are incapacitated, medical personnel must know you are steroid-dependent.

7. How does Addison’s affect my blood pressure?
Low aldosterone leads to sodium loss and water depletion, causing chronic hypotension.

8. Can I live a normal life with this diagnosis?
Yes. Most patients lead full, active lives with proper adherence to the hormone replacement regimen.

9. Are there foods I should avoid?
There are no specific dietary restrictions, but maintaining adequate salt and fluid intake is crucial.

10. How often should I see my endocrinologist?
Stable patients typically require follow-up every 6–12 months to adjust dosages and monitor for complications like osteoporosis or thyroid dysfunction.

10. Conclusion

Late-onset Addison’s Disease represents a clinical challenge that demands vigilance. By integrating a high level of suspicion with standardized diagnostic protocols and patient-centered education, clinicians can effectively manage this condition, preventing the catastrophic outcomes associated with adrenal crisis and significantly improving the quality of life for the aging patient.